Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2026-01-05 @ 2:28 AM
Study NCT ID:
NCT02797067
Status:
COMPLETED
Last Update Posted:
2022-05-26
First Post:
2016-05-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Rectal Indomethacin to Prevent Post ESWL-pancreatitis
Sponsor:
Changhai Hospital
Organization:
Study Overview
Official Title:
Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIPEP
Brief Summary:
The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.
Detailed Description:
It is a prospective, double-blind, randomized controlled trial. Patients with painful chronic pancreatitis and pancreatic stones (\> 5 mm in diameter) who are treated with ESWL at Changhai Hospital will be randomly allocated to indomethacin or placebo therapy before the procedure.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: